🇺🇸 FDA
Patent

US 11814432

Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof

granted A61KA61K2035/122A61K40/11

Quick answer

US patent 11814432 (Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof) held by SANGAMO THERAPEUTICS FRANCE expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SANGAMO THERAPEUTICS FRANCE
Grant date
Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2035/122, A61K40/11, A61K40/22, A61K40/31